7-Methoxyisoflavone Clinical Trials

Size	Price	Qty
25mg	USD 99

Clinical Trials

Several clinical trials evaluate conditions associated with post-acute COVID-19 syndrome, neuromotor rehabilitation outcomes, and inflammatory biomarkers in populations affected by COVID-19 and rheumatoid arthritis. Sponsored by academic and hospital institutions including the University of Valladolid, Centro Hospitalario Padre Benito Menni, and Assiut University, these studies have phase classifications listed as not applicable or unassigned. Across these interventional and observational efforts, the recruitment status includes both completed studies and trials with an unknown status.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06137716	Completed	Robotic Exoskeleton\|Post-acute Covid-19 Syndrome\|Rehabilitation Outcome\|Physical And Rehabilitation Medicine	University of Valladolid\|Centro Hospitalario Padre Benito Menni	2022-07-01	Not Applicable
NCT05175638	Unknown status	COVID-19 Pandemic	Assiut University	2022-02	--
NCT04315818	Unknown status	Rheumatoid Arthritis	Assiut University	2021-03	--

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the 7-Methoxyisoflavone product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

7-Methoxyisoflavone acts as a potent activator of adenosine monophosphate-activated protein kinase (AMPK), promoting kinase phosphorylation and downstream cellular energy sensing. By enhancing metabolic regulation and suppressing pro-inflammatory signaling pathways, this AMPK activation demonstrates therapeutic potential in managing chronic inflammatory and recovery-related conditions studied in clinical settings, such as rheumatoid arthritis and post-acute COVID-19 syndrome.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).